Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Class action filed
Appointed CFO
Quarterly results
Director departure
Appointed director
CC transcript
|
|
OCLARO, INC. (OCLR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/16/2018 |
GN
| Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results |
| 08/15/2018 |
GN
| Report: Developing Opportunities within RA PHARMCTL INC, Oclaro, Emergent Biosolutions, Kennametal, Instructure, and Donegal Group — Future Expectations, Projections Moving into 2018 |
| 05/29/2018 |
GN
| Oclaro and Acacia Communications Collaborate on 100/200G CFP2-DCO Products |
| 02/15/2018 |
GN
| Investor Expectations to Drive Momentum within Workday, The Medicines, Celldex Therapeutics, Lannett, Oclaro, and Antares Pharma — Discovering Underlying Factors of Influence |
| 12/01/2017 |
GN
| Report: Exploring Fundamental Drivers Behind Lannett, Oclaro, Antares Pharma, Workday, The Medicines, and Celldex Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments |
|
|